Comparing belinostat or pralatrexate with chemotherapy for PTCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding belinostat or pralatrexate to standard chemotherapy (CHOP) works better than CHOP alone for people newly diagnosed with peripheral T-cell lymphoma (PTCL). It aims to find a more effective first treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with a type of PTCL listed in the trial, like PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, or certain other subtypes.
- You have at least one tumor that can be measured by scans.
- You are physically well enough to be up and about most of the day (ECOG score 0-2).
- Your blood counts, liver function, and kidney function are within acceptable ranges (some flexibility if your lymphoma has affected these organs).
- You have not had prior treatment for PTCL and have not taken certain medications like belinostat or pralatrexate before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This study tests whether adding a targeted drug called linperlisib to the standard chemo regimen (CHOP) is better than CHOP alone for people with newly diagnosed peripheral T-cell lymphoma. It may help shrink tumors and control the lymphoma for longer.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.